Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Increases By 11.0%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the recipient of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 272,100 shares, an increase of 11.0% from the November 15th total of 245,200 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average trading volume of 348,600 shares, the days-to-cover ratio is currently 0.8 days.

Coeptis Therapeutics Price Performance

COEP traded up $0.01 during midday trading on Monday, hitting $0.19. The company had a trading volume of 634,118 shares, compared to its average volume of 340,084. Coeptis Therapeutics has a twelve month low of $0.15 and a twelve month high of $0.97. The firm’s 50-day simple moving average is $0.20 and its 200-day simple moving average is $0.22. The company has a market capitalization of $7.85 million, a PE ratio of -0.66 and a beta of -0.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.40 and a current ratio of 0.40.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.